Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-PREDICT-HER2: Predictive Markers for Chemo-immunotherapy in HER2+ Early Breast Cancer
NCT01891357Phase 2Terminated
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Sep 2013
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in HER2-positive breast cancer, sponsored by Westdeutsche Studiengruppe. Started Sep 2013; status: terminated.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01891357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01891357.